Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Zacks Investment Research

Palisade Bio (NASDAQ:PALIGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif. “

Separately, LADENBURG THALM/SH SH assumed coverage on shares of Palisade Bio in a research report on Wednesday, February 2nd. They issued a “buy” rating and a $5.00 price objective for the company.

Shares of NASDAQ:PALI opened at $0.84 on Wednesday. Palisade Bio has a 12 month low of $0.76 and a 12 month high of $10.91. The firm’s 50-day moving average is $0.96 and its 200 day moving average is $1.57.

A number of institutional investors and hedge funds have recently modified their holdings of PALI. Altium Capital Management LP acquired a new position in shares of Palisade Bio in the 4th quarter valued at about $434,000. Geode Capital Management LLC increased its stake in shares of Palisade Bio by 21.6% in the 4th quarter. Geode Capital Management LLC now owns 208,563 shares of the company’s stock valued at $271,000 after purchasing an additional 37,033 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Palisade Bio in the 4th quarter valued at about $105,000. Northern Trust Corp purchased a new position in shares of Palisade Bio in the 4th quarter valued at about $30,000. Finally, Sargent Investment Group LLC purchased a new position in shares of Palisade Bio in the 3rd quarter valued at about $278,000. 5.83% of the stock is owned by institutional investors.

Palisade Bio Company Profile (Get Rating)

Palisade Bio, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery.

Featured Articles

Get a free copy of the Zacks research report on Palisade Bio (PALI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.